


# ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Sara A Hurvitz,<sup>1</sup> **Anne F Schott**,<sup>2</sup> Cynthia Ma,<sup>3</sup> Erika P Hamilton,<sup>4</sup> Rita Nanda,<sup>5</sup> George Zahrah,<sup>6</sup> Natasha Hunter,<sup>7</sup> Antoinette R Tan,<sup>8</sup> Melinda L Telli,<sup>9</sup> Jesus Anampa Mesias,<sup>10</sup> Rinath Jeselsohn,<sup>11</sup> Pamela Munster,<sup>12</sup> Haolan Lu,<sup>13</sup> Richard Gedrich,<sup>13</sup> Cecile Mather,<sup>13</sup> Janaki Parameswaran,<sup>13</sup> Hyo S Han<sup>14</sup>

<sup>1</sup>UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; <sup>2</sup>Rogel Cancer Center, University of Michigan Health, Ann Arbor, MI; <sup>3</sup>Washington University, St Louis, MO; <sup>4</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; <sup>5</sup>University of Chicago Medicine, Chicago, IL; <sup>6</sup>Norwalk Hospital, Norwalk, CT; <sup>7</sup>Seattle Cancer Care Alliance, Seattle, WA; <sup>8</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC; <sup>9</sup>Stanford University School of Medicine, Stanford, CA; <sup>10</sup>Albert Einstein College of Medicine, Bronx, NY; <sup>11</sup>Dana-Farber Cancer Institute, Boston, MA; <sup>12</sup>University of California San Francisco, San Francisco, CA; <sup>13</sup>Arvinas Operations, Inc, New Haven, CT; <sup>14</sup>Moffitt Cancer Center, Tampa, FL

# Background

- ARV-471 is a selective, orally administered PROTAC® protein degrader that targets wild-type and mutant ER<sup>1</sup>
- ARV-471 directly binds an E3 ubiquitin ligase and ER to trigger ubiquitination of ER and its subsequent proteasomal degradation
  - In contrast, SERDs indirectly recruit the ubiquitin-proteasome system, secondary to conformational changes and/or immobilization of ER<sup>2</sup>
- Limitations of the SERD fulvestrant include its intramuscular route of administration<sup>3</sup> and only 40%–50% ER protein degradation at its optimal dose<sup>4,5</sup>
- ARV-471 treatment yielded substantially greater ER degradation and tumor growth inhibition than fulvestrant in breast cancer xenograft models<sup>1</sup>



ER=estrogen receptor; PROTAC=PROteolysis TARgeting Chimera; SERD=selective estrogen receptor degrader

1. Flanagan, JJ, et al. *Cancer Research*. 2019;79(4 Suppl):P5-04.

3. Nathan MR and Schmid P. *Oncol Ther*. 2017;5:17-29.

5. Robertson JFR, et al. *Breast Cancer Res*. 2013;15(2).R18.

2. Hanker AB, et al. *Cancer Cell*. 2020;37(4):496-513.

4. Kuter I, et al. *Breast Cancer Res Treat*. 2012;133(1):237-246.

# Phase 1/2 Study Design<sup>a</sup>

First-in-human, open-label, 3-part study of ARV-471 alone or in combination with palbociclib in patients with ER+/HER2- locally advanced/metastatic breast cancer

## Phase 1 dose escalation (Part A)

### Treatment

- ARV-471 orally

### Primary objective

- Evaluate the safety and tolerability of ARV-471 in order to estimate the MTD and select the RP2Ds

## Phase 2 cohort expansion (Part B; VERITAC)

### Treatment

- ARV-471 orally

### Primary objective

- Assess the antitumor activity of ARV-471

## Phase 1b combination (Part C)

### Treatment

- ARV-471 plus palbociclib orally

### Primary objective

- Evaluate the safety and tolerability of ARV-471 plus palbociclib and select the RP2D of the combination

<sup>a</sup>ClinicalTrials.gov: NCT04072952

ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; MTD=maximum tolerated dose; RP2D=recommended phase 2 dose

# Phase 1 ARV-471 Dose Escalation Results<sup>1</sup>

## Phase 1 dose escalation (Part A)

### Treatment

- ARV-471 orally

### Primary objective

- Evaluate the safety and tolerability of ARV-471 in order to estimate the MTD and select the RP2Ds

- As of September 30, 2021, 60 patients received ARV-471
  - Total daily doses ranged from 30–700 mg
- ARV-471 was well tolerated at all doses, with no DLTs or grade  $\geq 4$  TRAEs; most TRAEs were grade 1/2
- The CBR<sup>a</sup> was 40% (95% CI: 26–56) in 47 evaluable patients
- 3 patients had confirmed PRs
- Preliminary PK data showed dose-related increases for AUC<sub>24</sub> and C<sub>max</sub> from 30–500 mg daily doses
- At the 200-mg and 500-mg doses, mean exposure on day 15 exceeded the nonclinical efficacious range by >2-fold and >5-fold, respectively<sup>2</sup>
- ER degradation up to 89% was observed; median and mean ER degradation across dose levels was 67% and 64%, respectively

<sup>a</sup>Rate of confirmed complete response or partial response or stable disease  $\geq 24$  weeks; evaluable patients were enrolled  $\geq 24$  weeks prior to the data cutoff

AUC<sub>24</sub>=area under the curve from 0 to 24 hours; CBR=clinical benefit rate; C<sub>max</sub>=maximum plasma concentration; DLT=dose-limiting toxicity; ER=estrogen receptor; MTD=maximum tolerated dose; PK=pharmacokinetic; PR=partial response; RP2D=recommended phase 2 dose; TRAE=treatment-related adverse event

1. Hamilton E, et al. Presented at SABCS; Dec 7-10, 2021; Poster PD13-08.

2. Snyder LB, et al. Presented at AACR; April 10-15, 2021; Oral Presentation 44.

# Phase 2 (VERITAC) Cohort Expansion Design

## Phase 2 cohort expansion (Part B; VERITAC)

### Key eligibility criteria

- Histologically or cytologically confirmed ER+ and HER2- advanced breast cancer
- Measurable or nonmeasurable disease per RECIST criteria v1.1
- ≥1 prior endocrine regimen (≥1 regimen for ≥6 months in the locally advanced or metastatic setting)
- ≥1 prior CDK4/6 inhibitor
- ≤1 prior chemotherapy regimen in the locally advanced or metastatic setting

**ARV-471  
200 mg orally QD<sup>a</sup>  
(n=35)**

**ARV-471  
500 mg orally QD<sup>a</sup>  
(n=36)**

### Primary endpoint

- CBR (rate of confirmed CR or PR or SD ≥24 weeks)<sup>b</sup>

### Secondary endpoints

- ORR, DOR, PFS, and OS
- AEs and laboratory abnormalities
- PK parameters

### Exploratory endpoints

- *ESR1* mutational status
- ER protein levels

### Data cutoff date for this analysis

- June 6, 2022

<sup>a</sup>Enrollment in the 200-mg QD cohort began before enrollment in the 500-mg QD cohort

<sup>b</sup>Analyzed in patients enrolled ≥24 weeks prior to the data cutoff

AE=adverse event; CBR=clinical benefit rate; CDK=cyclin-dependent kinase; CR=complete response; DOR=duration of response; ER=estrogen receptor; *ESR1*=estrogen receptor 1 gene; HER2=human epidermal growth factor receptor 2; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; PK=pharmacokinetic; PR=partial response; QD=once daily; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease

# Patient Baseline Characteristics (VERITAC)

Characteristic	Total (N=71)
Sex, n (%)	
Female	69 (97.2)
Median age, y (range)	60 (41–86)
ECOG PS, n (%) <sup>a</sup>	
0	47 (66.2)
1	23 (32.4)
Visceral disease, n (%)	39 (54.9)
Sites of metastasis, n (%)	
Bone	49 (69.0)
Liver	32 (45.1)
Lung	17 (23.9)
Other	5 (7.0)

Characteristic	Total (N=71)
Baseline <i>ESR1</i> status, n (%) <sup>b</sup>	
Mutant	41 (57.7)
Wild-type	25 (35.2)
Median no. of prior regimens (range)	
Any setting	4 (1–10)
Metastatic setting	3 (0–7)
Type of prior therapy, n (%)	
CDK4/6 inhibitor	71 (100)
Aromatase inhibitor	64 (90.1)
Fulvestrant	56 (78.9)
Chemotherapy	
Any setting	52 (73.2)
Metastatic setting	32 (45.1)

<sup>a</sup>Baseline ECOG PS status was unknown in 1 patient. <sup>b</sup>Baseline *ESR1* status was unknown or missing in 5 patients

CDK=cyclin-dependent kinase; ECOG PS=Eastern Cooperative Oncology Group performance status; *ESR1*=estrogen receptor 1 gene

# Treatment-Emergent Adverse Event Summary (VERITAC)

n (%)	200 mg QD (n=35)	500 mg QD (n=36)	Total (N=71)
TEAEs			
Any grade	32 (91)	30 (83)	62 (87)
Grade 3/4	9 (26)	6 (17)	15 (21)
Grade 5 <sup>a</sup>	1 (3)	0	1 (1)
Leading to discontinuation	1 (3)	2 (6)	3 (4)
Leading to dose reduction	0	3 (8)	3 (4)

- Dose reductions due to TEAEs
  - 500-mg QD cohort (to 400 mg QD)
    - ALT increased (n=1)
    - Neutropenia (n=1)
    - Fatigue (n=1)
- Discontinuations due to TEAEs
  - 200-mg QD cohort
    - QT prolongation (n=1)<sup>b</sup>
  - 500-mg QD cohort
    - ECG T-wave abnormality (n=1)<sup>c</sup>
    - Back pain/spinal cord compression (n=1)

<sup>a</sup>Acute respiratory failure in the setting of disease progression and unrelated to ARV-471 treatment

<sup>b</sup>Patient had QT prolongation at baseline, received a concomitant QT-prolonging drug during ARV-471 treatment, and had hypokalemia

<sup>c</sup>Patient had ECG T-wave abnormality at baseline

ALT=alanine aminotransferase; ECG=electrocardiogram; QD=once daily; TEAE=treatment-emergent adverse event

# TRAEs Reported in $\geq 10\%$ of Patients Overall (VERITAC)

n (%)	200 mg QD (n=35)			500 mg QD (n=36)			Total (N=71)		
	Grade 1	Grade 2	Grade 3/4 <sup>a</sup>	Grade 1	Grade 2	Grade 3/4 <sup>b</sup>	Grade 1	Grade 2	Grade 3/4
Any TRAE	13 (37)	13 (37)	2 (6)	11 (31)	9 (25)	3 (8)	24 (34)	22 (31)	5 (7)
Fatigue	8 (23)	6 (17)	0	7 (19)	2 (6)	1 (3)	15 (21)	8 (11)	1 (1)
Nausea	2 (6)	3 (9)	0	6 (17)	1 (3)	0	8 (11)	4 (6)	0
Arthralgia	4 (11)	0	0	5 (14)	0	0	9 (13)	0	0
Hot flush	6 (17)	0	0	1 (3)	0	0	7 (10)	0	0
AST increased	3 (9)	1 (3)	0	2 (6)	1 (3)	0	5 (7)	2 (3)	0

<sup>a</sup>Grade 3/4 TRAEs in the 200-mg QD cohort were grade 3 QT prolonged (n=1; same TEAE that led to discontinuation as shown in the prior slide) and grade 3 thrombocytopenia and grade 4 hyperbilirubinemia (n=1)

<sup>b</sup>Grade 3/4 TRAEs in the 500-mg QD cohort were grade 3 fatigue, decreased appetite, and neutropenia (n=1 each)

AST=aspartate aminotransferase; QD=once daily; TEAE=treatment-emergent adverse event; TRAE=treatment-related adverse event



## Primary Endpoint: Clinical Benefit Rate<sup>a</sup> (VERITAC)

	200 mg QD (n=35)	500 mg QD (n=36)	Total (N=71)
CBR, % (95% CI)	37.1 (21.5–55.1)	38.9 (23.1–56.5)	38.0 (26.8–50.3)

<sup>a</sup>Rate of confirmed complete response or partial response or stable disease  $\geq$ 24 weeks  
CBR=clinical benefit rate; QD=once daily

# Primary Endpoint: Clinical Benefit Rate<sup>a</sup> (VERITAC)


	200 mg QD (n=35)	500 mg QD (n=36)	Total (N=71)
CBR, % (95% CI)	37.1 (21.5–55.1)	38.9 (23.1–56.5)	38.0 (26.8–50.3)
Patients with mutant <i>ESR1</i>	(n=19)	(n=22)	(n=41)
CBR, % (95% CI)	47.4 (24.4–71.1)	54.5 (32.2–75.6)	51.2 (35.1–67.1)

<sup>a</sup>Rate of confirmed complete response or partial response or stable disease  $\geq 24$  weeks  
CBR=clinical benefit rate; *ESR1*=estrogen receptor 1 gene; QD=once daily




# Progression-Free Survival<sup>a</sup> (VERITAC)

	All Patients	
	200 mg QD (n=35)	Total (N=71)
Events, n (%)	24 (68.6)	41 (57.7)
mPFS, mo (95% CI)	3.5 (1.8–7.8)	3.7 (1.9–8.3)



	Mutant <i>ESR1</i>	
	200 mg QD (n=19)	Total (n=41)
Events, n (%)	12 (63.2)	22 (53.7)
mPFS, mo (95% CI)	5.5 (1.8–8.5)	5.7 (3.6–9.4)



<sup>a</sup>Limited follow-up in 500-mg QD cohort led to ≥50% of patients censored for PFS (curve not shown)

*ESR1*=estrogen receptor 1 gene; mPFS=median progression-free survival; PFS=progression-free survival; QD=once daily



# Conclusions

- ARV-471 showed clinical activity in the VERITAC expansion cohorts of heavily pretreated patients (4 median prior regimens, 100% with prior CDK4/6 inhibitors, and 79% with prior fulvestrant) with ER+/HER2- advanced breast cancer
  - CBR was 37.1% and 38.9% in the 200- and 500-mg QD cohorts, respectively
  - Clinical benefit was also observed in the *ESR1* mutation subgroup (CBR of 47.4% and 54.5% in the 200- and 500-mg QD cohorts, respectively)
- ARV-471 had a manageable AE profile; most AEs were grade 1/2
- ARV-471 200 mg QD was selected as the phase 3 monotherapy dose based on comparable efficacy, favorable tolerability, and robust ER degradation

AE=adverse event; CBR=clinical benefit rate; CDK=cyclin-dependent kinase; ER=estrogen receptor; *ESR1*=estrogen receptor 1 gene; HER2=human epidermal growth factor receptor 2; QD=once daily

# Phase 3 VERITAC-2 Trial

## Key eligibility criteria

- Women or men aged ≥18 years
- Confirmed ER+/HER2- advanced breast cancer
- 1 line of CDK4/6 inhibitor therapy in combination with endocrine therapy
- ≤1 additional endocrine therapy
- Most recent endocrine treatment given for ≥6 months prior to disease progression
- No prior fulvestrant
- No prior chemotherapy for locally advanced/metastatic disease
- Radiological progression during or after the last line of therapy

R  
A  
N  
D  
O  
M  
I  
Z  
E  
1:1

## Treatment (N=560)

### ARV-471

200 mg orally once daily

### Fulvestrant

500 mg intramuscularly days 1 and 15 of cycle 1 and day 1 of subsequent cycles

## Stratification factors

- *ESR1* mutant (yes vs no)
- Visceral disease (yes vs no)

## Primary endpoint

- PFS by BICR in
  - ITT population
  - *ESR1* mutant population

## Secondary endpoints include:

- OS, ORR, DOR, and CBR<sup>a</sup>
- AEs
- QoL measurements

<sup>a</sup>Rate of confirmed complete response or partial response or stable disease ≥24 weeks

AE=adverse event; BICR=blinded independent central review; CBR=clinical benefit rate; CDK=cyclin-dependent kinase; DOR=duration of response; ER=estrogen receptor; *ESR1*=estrogen receptor 1 gene; HER2=human epidermal growth factor receptor 2; ITT=intention to treat; ORR=overall response rate; OS=overall survival; QoL=quality of life; PFS=progression-free survival

# Acknowledgments

- We thank the patients who participated in this study and their caregivers, as well as the investigators, researchers, and coordinators who contributed to this study
- This study is sponsored by Arvinas Estrogen Receptor, Inc
- Presentation development support was provided by Apollo Medical Communications and funded by Arvinas Operations, Inc

## Plain Language Summary

Please scan this Quick Response (QR) code with your smartphone app to view a plain language summary.

